Updated Guidance for Lete-cel; GSK / Haleon Business Separation Completed; GSK’s Q2 2022 Earnings Call Summary
On Wednesday, July 27, GSK held their Q2 2022 earnings call (presentation / press release) providing updated guidance for their lead cell therapy asset lete-cel (NY-ESO-1 TCR-T) and confirming the successful separation of the consumer healthcare business (Haleon). Below, Celltelligence provides insights on lete-cel’s potential approval while comparing with key competitor afami-cel (Adaptimmune’s MAGE-A4 SPEAR-T).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.